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Abstract
The incidence of hepatocellular carcinoma (HCC) is steadily increasing in worldwide, 
which has been a public concern significantly associated with diabetes and non-alcoholic 
fatty liver disease (NAFLD) is an emerging risk factor with increasing prevalence nowa-
days, with gradually instead of HBV and HCV, aflatoxin, or alcohol liver disease as major 
etiological factors. The deeply worrisome aspects of these high risk factors are their large 
spread in population. Systemic and genetic mechanisms involved in malignant trans-
formation of liver cells as well as useful biomarkers at early stage of HCC are being 
investigated. However, the exact mechanisms from NAFLD to HCC still remain to be 
explored. In this paper, some advances of liver lipid accumulation were summarized on 
the relationship between NAFLD and hepatocytes malignant transformation.
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1. Introduction
Hepatocellular carcinoma (HCC) is one of the fifth most common malignant tumors, the third 
most frequent cause of cancer mortality worldwide [1, 2], and ranks the second in China 
among all malignancies with its mortality almost equal to its morbidity, especially in the 
inshore area of the Yangtze River [3, 4]. The principal treatment of HCC patient is surgical 
resection or liver transplantation, depending on whether the patient is a suitable transplant 
candidate [5, 6]. However, in most HCC patients with diagnosis at early stage is very dif-
ficult, thereby excluding the patients from definitive surgical resection. Sorafenib, the most 
commonly used systemic therapy, has shown to only minimally impact on patient survival 
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by several months. Besides, neither chemotherapy nor radiotherapy are generally effective. 
Due to the poor prognosis of HCC patients, the early diagnosis and effective therapy of HCC 
are needed with several being in development, either in preclinical or clinical studies [7, 8].
The development of HCC is a complex multi-step process involved multiple genes. Major risk fac-
tors of HCC include hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, alcoholic or non-
alcoholic fatty liver disease, nitrosamines, aflatoxin, and other harmful substances [9–12]. Chronic 
persistent infection of nonalcoholic is still the main pathological factor of inducing cirrhosis and 
HCC. However, with the changes of people’s dietary structure and lifestyle, the incidence of fatty 
liver disease (FLD) also rose sharply [13–15]. A median prevalence of alcoholic fatty liver disease 
(AFLD) and nonalcoholic fatty liver disease (NAFLD) is 4.5 and 15.0%, respectively [16, 17]. It is 
worrying that if no interference is conducted in the treatment, nonalcoholic steatohepatitis (NASH) 
or alcoholic hepatitis can also be developed for liver fibrosis, cirrhosis and liver cancer (Figure 1), 
and its exact mechanism is worth exploring. However, the underlying molecular mechanisms that 
lead to malignant transformation of infected liver cells still remain to be explored. Most of HCC 
patients died quickly because of the rapid tumor growth, and surgical operation or liver transplan-
tation still is the only effective treatment for HCC [18, 19]. This article summarizes new advances 
on relationship between NAFLD and hepatocytes malignant transformation.
2. Mitochondria and fatty β-oxidation
2.1. Mitochondria
Liver is one of the most important organs in human for maintaining energy supply and lipid 
metabolism [20, 21]. The peroxisomal compartment in hepatocytes hosts several essential 
Figure 1. NAFLD progression and clinical diagnosis. ALT: alanine aminotransferase, NAFLD: non-alcoholic fatty liver 
disease, NAFL: nonalcoholic fatty liver, NASH: non-alcoholic steatohepatitis, HCC: hepatocellular carcinoma, HBsAg: 
hepatitis B surface antigen, HCV: hepatitis C virus, ANA: antinuclear antibody.
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metabolic conversions. Upon nutrient deprivation, cells metabolize fatty acids (FAs) in mito-
chondria to supply energy. FAs mobilization depends on triacylglycerol lipolysis, whereas 
autophagy feeds the lipid droplet pool for continued fueling of mitochondria. Proteome 
imbalance of mitochondrial electron transport chain in brown adipocytes leads to metabolic 
benefits [22]. Lipid metabolism are defective in peroxisomal disorders that are either caused 
by failure to import the enzymes such as carnitine palmitoyltransferase (CPT) in the organelle 
or by mutations in the enzymes or in transporters needed to transfer the substrates across the 
peroxisomal membrane (Figure 2). Hepatocytes specific differences have been confirmed in 
mitochondrial DNA maintenance and expression [23]. Hepatic pathology is one of the cardi-
nal features in disorders of peroxisome biogenesis and peroxisomal β-oxidation, although it 
rarely determines the clinical fate. Besides of the morphological changes, the impact of peroxi-
some malfunctions on other cellular compartments includes thermal instability of carnitine 
palmitoyltransferase II (CPT-II) variants in mitochondria and endoplasmic reticulum (ER) 
[24–26]. Proteomics analysis revealed numerous enzymes expression involved with the elec-
tron transport system, the tricarboxylic acid cycle, as well as lipid and amino acid metabolism 
in response to anoxia exposure [27].
Figure 2. Fatty acid oxidation and ATP production in mitochondria. The distribution of mitochondrial CPT-I or CPT-II 
with regulation plays important roles in fatty acid metabolism. Fatty acid (FA) β-oxidation requires successive carnitine 
acyltransferases to translocate acyl-coenzyme As (acyl-CoAs) from the cytoplasm into matrix. As initial and rate-limiting 
CPT-I generates acylcarnitines that traverse mitochondrial membranes via specific transporters into matrix, CPT-II 
produces acyl-CoAs from acylcarnitines for FA β-oxidation to acetyl-CoA. Then carnitine crosses the inner membrane, 
binds with the endogenous or exogenous acyl CoA to prevent acyl CoA accumulation causing poisoning. ACC: acetyl 
CoA carboxylase, CoA: coenzyme A, TCA: tricarboxylic acid cycle, UCP: uncoupling protein, I II III IV: electron transfer 
complex [29].
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2.2. Carnitine level
Carnitine is a physiological substance that is essential for the proper metabolism of fat 
and energy production that actually transports both long and medium fatty acid chains. 
L-carnitine attracts long and medium fatty acid chains, breaks them down, and carries them 
to the mitochondria of the cells where they are metabolized (burned). The L-carnitine plays 
important roles in the catabolism of long-chain fatty acids in the mitochondria, not only due 
to increased mitochondrial fatty acid oxidation reflected by increased mitochondrial biogen-
esis, but also to changes in plasma clearance and reduced triacylglycerol (TAG) biosynthesis 
[28]. The ultimate result is that you burn more fats, and in the process give your body more 
natural energy. In the previous study, the increasing liver weight with lipid accumulation 
was discovered during the course of the wild-type mice (Figure 3) in circulating carnitine 
analogues [3-(2,2,2-trimethyl hydrazinium) propionate dihydrate, THP] [29, 30].
Figure 3. Liver lipid accumulation and liver weight tissues in mice models after carnitine analogues. A–D, the mice liver 
tissues with Oil red O staining: A & B, the control livers; C & D, the experimental livers; E, the alterations of different 
tissue weight after the experimental mice with carnitine analogues [29].
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2.3. Carnitine palmitoyltransferase (CPT)
Hepatic CPT-II is a mitochondrial protein which is transported to mitochondrial inner 
membrane. It together with CPT-I oxidizes long-chain fatty acids in mitochondria. Defects 
or mutation of this gene are associated with mitochondrial long-chain fatty-acid oxidation 
disorders. Decreasing of its activity is a disorder of mitochondrial fatty acid oxidation with 
autosomal recessive mode of inheritance. The variants exert a dominant-negative effect 
on the homotetrameric protein of the enzyme (Figure 4), with reduced activities, thermal 
instability, fatty acid β-oxidation decreased to 30–59%, intracellular ATP to 48–79%, a sig-
nificantly decreasing of mitochondrial membrane potential with increasing temperature at 
Figure 4. Mutation of CPT-II gene and hepatic lipid accumulation. (A) The CPT-II gene exon 1–5. (B) The sequence 
fragments of CPT-II gene exon 4 were amplified on mitochondrial inner membrane. The mutation analysis of CPT-II 
gene exon-4 using the specific primers were designed by sequencing with 1974 nucleotides coded 658 amino acids. 
Compared with the original sequence from Genbank, the two substitution sites were found at 1618 (G→A) and 1858 
(T→C), and code amino acids at V368I and F448L, respectively [29].
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Figure 5. Rat liver tissues and their pathological examination. Liver alterations after the rats (from left to right: upper, 
A, B, C, D, and E; under A1, B2, C3, D4, and E5) were sacrificed at different time according to the plan schoule. (A) A 
representative liver from rat with normal diet; (B) a representative liver from the rat with high-fat diet (HFD) without 
2-fluorenyl acetamide (2-FAA); (C) a representative liver from the rats with HFD containing 2-FAA at early stage; (D) a 
representative liver at interim stage; and (E) a representative liver at later stage. The liver sections were examined with 
hematoxylin and eosin staining and then divided into the control (A1), fatty liver (B1), degeneration (C1), precancerous 
(D1), and cancerous (E1) groups; A1-E1: The original magnification of the corresponding rat liver sections was ×200 [29].
41°C, and shortening half-lives of CPT-II, and the enzyme variant proteins were polyubiq-
uitinated and rapidly degraded by a lactacystin-sensitive proteasome pathway [24]. The 
very unstable CPT II variants with decreased enzymatic activities may bring mitochondrial 
fuel utilization below the phenotypic threshold during high fever in humans with hepatitis 
virus infection, and thus might be as novel potential mechanisms for NAFLD formation 
[31, 32].
The dynamic alterations of hepatic CPT-II expression in the mitochondrial inner membrane 
were investigated during the malignant transformation of hepatocytes induced by abnormal 
fatty accumulation. After the male Sprague-Dawley (SD) rats were fed with control, high 
fat (HF), and HF containing 2-fluorenylaceta-mide (2-FAA) diet, respectively. The rats were 
divided into control, fatty liver, degeneration, pre-cancerous, and cancerous groups according 
to the hematoxylin and eosin staining (H&E) of liver pathological examination, hepatic lipids 
accumulation were confirmed with the Oil Red O staining. Massive lipid accumulation hepa-
tocytes were seen in rats on HF and HF containing 2-FAA diets. The lipid levels in the control 
group were significantly lower than those in the fatty liver, degeneration, precancerous, and 
cancerous groups. The serum triglyceride and total cholesterol levels in the degeneration, 
precancerous, and cancerous groups were 2–3 times higher than those in the control group. 
The serum aspartate aminotransferase and alanine aminotransferase levels (Figure 5) in the 
degeneration, precancerous, and cancerous groups were significantly higher (4–8 times) than 
those in the control group. The specific concentration (μg/mg protein) of liver CPT-II expres-
sion was significantly reduced during hepatocyte malignant transformation, as confirmed 
by immunohistochemistry, with the CPT-II levels significantly lower in the cancerous group 
than in any of other groups, indicated that low hepatic CPT-II expression might lead to abnor-
mal lipid accumulation in hepatocytes, which should promote the malignant transformation 
of hepatocytes [33, 34].
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3. Abnormal liver lipid accumulation
3.1. Lipid accumulation
Lipid accumulation in liver or HCC will cause tumor-associated molecular signaling alteration 
including NF-κB (nuclear factor-kappa B), JNK (c-Jun N-terminal kinase)/activation protein-1 
activation, and alterations of HCC development-related genes, respectively. For example, 
liver unsaturated fatty acids (UFA) inhibit the expression of phosphatase and tensin homolog 
(PTEN) deleted on chromosome 10 (10q23.3) via activating NF-κB/mTOR (mammalian target 
of rapamycin) complex [35]. As a tumor suppressor gene PTEN regulates the PKB/akt (serine-
threonine kinase protein kinase B) pathway, and PTEN deficiency induces the proliferation 
of hepatocytes by inhibiting cell apoptosis and promoting HCC formation confirmed in mice 
models with the PTEN deficiency in resembling non-alcoholic steatohepatitis (NASH) fea-
tures with developing steatosis, and inflammation damages or fibrosis in liver tissues [36].
DNA injury affects hepatic lipid metabolism. Reactive oxygen species (ROS) is an important 
factor in carcinogenesis. It can be induced in NAFLD patients with contiguous DNA damage 
by some of hepatic inflammatory cytokines or hepatitis virus infection and react with poly-
unsaturated fatty acids derived from hepatocyte membrane phospholipids, and subsequently 
results in reactive aldehydes production as lipid oxidation (LPO) byproducts, for example, 
4-hydroxynonenal (4 HNE) that can react with DNA to form mutagenic exocyclic etheno-
DNA adducts. Importantly, they are preferably formed in codon 249 of TP53, resulting in inac-
tivation of tumor suppressor p53 gene, secondary growth advantage, and anti-apoptosis [37].
3.2. Adipokines
Adipokine is a plethora of pro- and anti-inflammatory cytokines that secretes from adipose 
tissue with low-grade inflammation. Adiponectin and leptin have evolved as crucial signals 
in many obesity-related pathologies including (NAFLD) [38–40]. Adiponectin regulates the 
metabolism of blood glucose and hepatic fatty acid, and is decreased in NAFLD that might 
be critically involved in the pro-inflammatory state associated with obesity and related dis-
orders, overproduction of leptin, a rather pro-inflammatory mediator, is considered of equal 
relevance [41, 42]. An imbalanced adipokine profile in obesity consecutively contributes to 
metabolic inflammation in NAFLD, which is also associated with a substantial risk for devel-
oping HCC in the non-cirrhotic stage of disease [43, 44]. Both related to liver tumorigenesis 
especially in preclinical models, especially in hepatic satellite cell activation with stimulating 
the tissue inhibitor of metalloproteinase 1 production via the JAK/STAT (Janus kinase/signal 
transducer and activator of transcription) pathway promoting fibrogenesis [45, 46], or angio-
genesis or progression from NASH to HCC that has been confirmed in mice models [47, 48].
According to the data from animal models with HCC cell lines, adiponectin could increase 
JNK activation and induce cell apoptosis with AMPK alteration, which could inhibit mTOR 
phosphorylation, xenograft growth, tumor growth and metastasis by suppression of tumor 
angiogenesis in nude mice. However, lower circulating adiponectin favors tumorigenesis in 
NASH model [49]. Adipose-derived tumor necrosis factor is a potent activator of pro-oncogenic 
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pathways involving in mTOR, JNK, NF-κB, and extra-cellular signal-regulated kinases; 
Interleukin-6 (IL-6) combining with its receptors on liver or non-parenchymal cells can promote 
signal-transmuting receptor (gp130) complex with IL-6R activating JAK1 signaling, and STAT3 
activation or phosphorylation promotes the proliferation and anti-apoptosis of cancer cells [50], 
indicated that adiponectin coefficient action from adipose tissues and related- cytokines affect 
fatty acid metabolism and hepatocyte malignant transformation via many signal molecules.
4. Inducing roles of related proteins
4.1. Sterol regulatory element-binding proteins (SREBPs)
Lipid reprogramming has been considered as a crucial characteristic in HCC initiation and pro-
gression. SREBPs are the key transcription regulators of hepatic lipogenesis, and activate hepatic 
steatosis at the early stage. Tat-interacting protein 30 (TIP30) is a tumor suppressor protein that 
has been found to be expressed in a wide variety of tumor tissues that is involved in the control of 
cell apoptosis, growth, metastasis, angiogenesis, DNA repair, and tumor cell metabolism. TIP30 
regulates lipid metabolism in human HCC by regulating SREBP1 (sterol regulatory element-
binding protein 1) through the Akt/mTOR signaling pathway [51, 52]. In human HCC tissues, 
SREBP1 could significantly induce lipogenesis and be associated with a poor prognosis [53].
SREBP1c gene at mRNA level was up-regulated in human HCC tissues and not in their adjacent 
non-cancerous or non-cancerous liver tissues. The inhibition of SREBP1 expression resulted in 
growth arrest and apoptosis of cancerous cells, and increased the cell proliferation ability. HBx 
(HBV protein X) expression induces lipid accumulation in hepatic cells mediated by the induc-
tion of SREBP1, a key regulator of lipogenic genes in the liver. HBx interacts with LXRalpha 
(liver X receptor alpha) and enhances the binding of LXRalpha to LXRE (LXR-response ele-
ment), thereby resulting in the up-regulation of SREBP1 and fatty acid synthase, suggested 
that HBV infection can stimulate the SREBP1-mediated control of lipid accumulation [54].
4.2. Loss of tripartite motif 24 (TRIM24)
Aberrantly high expression of TRIM24 occurs in human HCC clinical samples and positively 
correlated with HCC tumor grade. Its knockdown inhibits proliferation and migration in HCC 
cells in vitro, with impeding of tumor growth in vivo [55, 56]. TRIM24 in mice is reportedly a 
liver-specific tumor suppressor, and appears to promote liver tumor development via AMPK 
signaling [57]. TRIM24 as an epigenetic co-regulator of some gene transcription that directly or 
indirectly inhibits mouse hepatic lipid accumulation, liver cell inflammation, liver fibrosis, and 
hepatocyte damage. Additionally, the global expression analyses of TRIM24−/− livers unveiled 
signaling pathways that closely associated with some features of NAFLD, inflammatory, cell 
apoptosis, and hepatocyte damage. The loss of liver TRIM24 expression could lead to the pro-
gression from patients with NAFLD to NASH or HCC in a time dependent manner [58].
4.3. Osteopontin (OPN)
According to accumulating data, human liver OPN is a multifunctional protein involved in 
some pathological alterations including hepatic immunity, hepatocytes inflammation, liver 
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fibrosis, and the development of HCC. Deficiency of OPN in obese mice fed with a high-fat 
diet reduced hepatic steatosis and inflammation, and liver cell ballooning, portal leukocyte 
infiltration and macrophage accumulation were attenuated. It is induced by Hedgehog sig-
naling, may directly promote pro-fibrogenic responses in steatohepatitis, or act as a paracrine 
factor secreted by bile duct or natural killer T cells (NKT), and also can be as an autocrine 
factor promoting fibrosis in hepatic satellite cells (HSC) [59].
The silencing OPN gene transcription by specific shRNA could result in increasing Bax, 
decreasing Bcl-2/Bcl-xL and X-linked inhibitor of apoptosis protein expression, and NF-κB 
activation, and induction of mitochondria-mediated apoptosis in HCCLM3 cells [19]. There 
were statistically significant differences in plasma OPN levels between the HCC group and 
the other groups. Regarding the validity of plasma OPN was a predictor of fatty change, with 
50% diagnostic accuracy, 70% sensitivity, 45% specificity, 50% positive predictive value, and 
75% negative predictive value at a cutoff value of 134 ng/mL. The data indicated that plasma 
OPN level could be of diagnostic potential value in NAFLD [60].
5. Promoting role of related cells
5.1. Hepatic satellite cells (HSC)
Human hepatic satellite cells (hHSC) in the perisinusoidal space between sinusoids and hepa-
tocytes are the predominant fibrogenic cells in liver tissues, and activated by liver cell injury to 
transdifferentiate from a quiescent state to proliferate matrix producing myofibroblasts [61–63]. 
The excessive production of extra-cellular matrix might result in cirrhosis occurrence. Human 
amphiregulin could increase the cell proliferation via EGFR, PI3K, and p38 mitogenic signal-
ing pathways, inducing significantly up-regulation of fibrogenic biomarkers, confirmed by 
the mice NASH model that exhibited rapid progression of advanced fibrosis and HCC, with 
mimics histological, immunological and transcriptomic features of NASH, and a useful tool for 
preclinical drug testing [64, 65]. In addition, fatty liver as a pro-metastasis microenvironment 
with hHSCs could promote HCC migration and proliferation. Fasting and specific microRNAs 
could inhibit hHSC activation or potentiate anti-cancer activity of Sorafenib in HCC [66, 67].
5.2. Immune cells
Activated immune cells interact with cells in tissues by metabolic stress will migrate to liver 
and drive the progression from NAFLD to HCC. The dysregulation of lipid metabolism in 
NAFLD from mice models or human samples causes a selective loss of intrahepatic CD
4
+ 
but not CD
8
+ T lymphocytes, leading to accelerated hepatocarcinogenesis via cross-talk with 
liver cells [68, 69]. The NKT cells primarily cause steatosis in liver tissues via secreted a type 
II trans-membrane protein (a TNF ligand super-family member, TNFSF14), and both of CD
8
+ 
and NKT cells cooperatively induce liver injury by feeding choline-deficient high-fat diet [70]. 
CD
4
+ T lymphocytes have greater mitochondrial mass than CD
8
+ T lymphocytes and generate 
higher levels of mitochondrially derived reactive oxygen species (ROS) [71].
Disruption of mitochondrial function by linoleic acid, a fatty acid accumulated in NAFLD, 
causes more oxidative damage than other free fatty acids such as palmitic acid, and mediates 
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selective loss of intrahepatic CD
4
+ T lymphocytes. Hepatic immune cells recognize cell injury 
or pathogen invasion with intracellular or surface-expressed pattern recognition receptors, 
subsequently initiating signaling cascades that trigger the release of factors promoting 
inflammatory response during NAFLD progression, demonstrating that the transition from 
NASH to HCC through liver cell lymphotoxin-β receptor (LTβR) and NF-κB signaling. In vivo 
blockade of ROS reversed NAFLD-induced hepatic CD
4
+ T lymphocyte decrease and delayed 
NAFLD-promoted HCC [72, 73].
5.3. Polyploidization
Polyploidization is one of the most dramatic genomic changes with rarely reported. The 
physiological events occur in liver development or adult life. However, the pathological poly-
ploidization takes place in NAFLD, a widespread metabolic disorder that maybe is a risk 
factor for HCC. The liver parenchyma in NAFLD models displayed the process alterations 
with a large ratio of highly polyploid mononuclear cells, but was not observed in normal liver 
parenchyma. Biopsies from NASH patients revealed the alterations in hepatocyte ploidy com-
pared with tissue from controls. Hepatocytes from NAFLD mice revealed that progression 
through the S/G2 phases of the cell cycle was inefficient and associated with activation of a 
G2/M DNA damage checkpoint, which prevented activation of the cyclin B1/CDK1 complex. 
The oxidative stress promotes the highly polyploid cells, and antioxidant- treated NAFLD 
hepatocytes resumed normal cell division and returned to normal state of polyploidy, indi-
cated that oxidative stress promote pathological polyploidization in NAFLD that might con-
tribute to HCC [74].
6. Alterations of small molecules
6.1. Oxidative stress
NAFLD is characterized by excess lipids in hepatocytes, due to excessive fatty acid influx from 
adipose tissue, de novo hepatic lipogenesis, in addition to excessive dietary fat and carbohy-
drate intake [44, 19]. Serious imbalance was found between limited antioxidant defenses and 
excessive formation of reactive species produced by liver oxidative stress such as ROS or RNS 
(reactive nitrogen species). Obese persons could increase free fatty acids uptake, stimulates 
FA oxidation for compensating excessive liver fat storage, and accelerate β-oxidation leads to 
increased production of ROS that damage mitochondrial membrane and DNA [75, 37].
Chronic lipid overload in hepatocytes induces mitochondrial oxidative stress or hepatocytes 
damage leading the NAFLD developing into a more severe liver disease condition, NASH, cir-
rhosis or HCC. Oxidative stress may induce endoplasmic reticulum (ER) dysfunction for liver 
malignancy. ER plays an important role in NAFLD pathogenesis, and consecutive increasing 
oxidative stress, inflammation and activation of NF-κB and JNK signaling pathways lead to 
the accumulation of intracellular lipids [76]. Extra-cellular signal-regulated protein kinase 
(ERK) is highly expressed in HCC via PIK13 activation. Among others, copper is one of the 
main bio-metals required for the preponderance of the enzymes involved in physiological 
redox reactions, which primarily occurs during mitochondrial respiration. Antioxidant food 
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agents recognized to improve NAFLD and its complications have been described in the 
copper-related literatures [77, 78].
6.2. Insulin resistance
NAFLD is associated with insulin resistance (IR) leading to a resistance in the antilipolytic 
effect of insulin in adipose tissue with an increase of FFAs. The increase of FFAs induces 
mitochondrial dysfunction and lipotoxicity [79]. Liver steatosis defined as lipid accumulation 
in hepatocytes is very frequently found in adults and obese adolescents. Etiologically, obesity 
and IR or excess alcohol intake are the most frequent causes of liver steatosis. Insulin as a key 
hormone regulates lipogenesis and lipolysis in adipose depots. The adipose tissue becomes 
resistant to the antilipolytic effect of insulin and FA release is increased with lipolysis or lipid 
intake, promoting triglyceride synthesis with lipid accumulation occurrence in livers [80, 81].
Liver lipid accumulation causes IR by the activation of NF-κB pathway and leads to hyperinsu-
linemia to activate phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway, implicated the 
malignant transformation of hepatocytes or in hepatocarcinogenesis [82]. Hyperinsulinemia 
up-regulates insulin-like growth factor-1 that stimulates cell proliferation and inhibits cell 
apoptosis [83]. Insulin activates insulin receptor substrate-1 (IRS-1) with up-regulating expres-
sion in HCC [84]. The IRS-1-mediated related-signaling molecules may act as survival factors, 
promote liver cell proliferation via mitogen-activated protein kinase and PI3K, and protect 
against transforming growth factor β1-induced apoptosis in HCC progression [85, 86].
6.3. Iron deposition
Liver is the main storage site for iron in the body because of its rich reticuloendothelial system 
[87]. Acquired hepatic iron overload is seen in a number of NAFLD patients. The dietary iron 
supplementation enhances experimental steatohepatitis induced by long-term high-fat diet 
feeding rats [88]. Excess liver iron may increase NASH risk and its progression to HCC [89, 
90]. Abnormal iron deposition in liver is more frequent in NASH patients, in which necroin-
flammation may be the driving factor. Iron and the coexistence of hyperinsulinemia are risk 
factors for NASH development and together they may contribute to insulin resistance, dis-
ease progression and HCC. Iron reduction has been proposed as treatment for dysmetabolic 
iron overload syndrome and NAFLD or iron deprivation can suppress HCC growth in vivo 
and in vitro experiments [91].
6.4. Alcohol
While tobacco and alcohol are established risk factors for HCC, the most common type of 
primary liver cancer [92]. Chronic alcohol intake results in the induction of liver cytochrome 
P450 2E1 leads to generation of ROS with direct or indirect carcinogenic consequences [93]. Many genetic factors regulating alcohol metabolism could predispose in developing alco-
holic pancreatitis or cirrhosis. Some studies revealed that alcohol could be metabolized by 
oxidative and non-oxidative. The main oxidative pathway includes alcohol dehydrogenase, 
aldehyde dehydrogenase, and cytochrome P450 2E1. In addition, neurocan in neuronal tissue is also expressed in liver and the common polymorphism of its gene rs2228603 is associated 
with HCC in alcoholic liver disease [94].
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6.5. MicroRNA (miR)
Regulating control miRs are highly conserved, small non-coding RNAs (about 18–25 nucleo-
tides in length) regulates transcription or translation of target genes and fatty acid metab-
olism. Both of miR-197 and miR-99 were associated with liver fibrosis in NASH patients. 
Altered miRNA expression was associated with activation of major hepatocarcinogenesis-
related pathways, including the TGF-β, Wnt/β-catenin, ERK1/2, mTOR, and EGF signaling. 
The over-expression of the miR-221-3p and miR-222-3p and oncogenic miR-106b~25 cluster 
was accompanied by the reduced protein levels of their targets, including E2F transcription 
factor 1, phosphatase and tensin homolog, and cyclin-dependent kinase inhibitor 1. miR-
93-5p, miR-221-3p, and miR-222-3p have been confirmed over-expressed in HCC. Aberrant 
expression of miRNAs may have mechanistic significance in NASH-associated liver carcino-
genesis and may serve as an indicator for the development of NASH-derived HCC [94, 95].
Some studies found that miR-122 is a key regulator of glucose and lipid metabolism in 
livers [96] and significantly higher circulating miR-122, miR-34a, and miR-16 expression 
were found in NAFLD. During the development of NAFLD patients with simple steatosis 
to steatohepatitis, the serological levels of miR-122 and miR-34a were positively correlated 
with disease severity, liver enzyme activities, fibrosis staging, active inflammation, and 
silencing of microRNA-122 is an early event during hepatocarcinogenesis from NASH [97], 
suggesting that the alteration of circulating miR-122 could be an early event from NASH to 
hepatocarcinogenesis..
7. Genetic factors
The development and progression of NAFLD are determined by environmental and genetic fac-
tors [10, 98]. The effect of genetic factors has been demonstrated by familial studies, twin studies 
and several cross-sectional studies. The data from the genome-wide association studies (GWAS) 
have shown that patatin-like phospholipase domain-containing protein 3 (PNPLA3) involved in 
metabolism of triglyceride on chromosome 22 is a genetic factor that promotes NASH develop-
ment, and PNPLA3 gene variant I148M showed a strong relationship with the development and 
progression of NAFLD, NASH, and NAFLD-related HCC. Single nucleotide polymorphism 
(SNP, rs738409) is closely related to fatty liver involved in fibrosis progression of NAFLD. The 
C<G variation in SNP rs738409 also increases HCC risk in NAFLD patients [99, 100].
The whole exome sequencing finds that apolipoprotein B mutations (c.6718A>T, K2240X) 
represent a paradigm of rare variant influencing liver fat content and HCC risk. Besides, the 
Patatin-like phospholipase domain-containing 3 [the trans-membrane 6 superfamily member 
2 (TM6SF2)] genes variant E167K was associated with NAFLD [101, 102]. Telomerase reverse 
transcriptase (TERT) mutations have been associated with hepatic steatosis. The deficiency 
of TERT can reduce the response to liver damage inducing the formation of steatosis and 
fibrosis. In conclusion, the occurrence of NAFLD-HCC seems to be influenced by common 
genetic variants as PNPLA3 and by rare genetic variants. Several genes have been proposed 
as candidate genes to be associated with NAFLD based on case–control studies [103].
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8. Microbiota and toxic substances
8.1. Gut microorganisms
NAFLD has become the most common chronic liver disease worldwide and is well-accepted 
that gut dysbiosis is associated with NAFLD [103]. The gut-liver axis has been proposed as 
a key player in the pathogenesis of NAFLD, as the passage of bacteria-derived products into 
the portal circulation could lead to a trigger of innate immunity, which in turn leads to liver 
inflammation. In intestine, there are trillions of microorganisms including bacteria, archaea, 
yeasts and viruses collectively called intestinal ecosystem through energy harvesting and fat 
storage [78, 104]. The relationship between gut microbiota and NAFLD is dependent on levels 
of choline, bile acid, larger production of endogenous ethanol, higher prevalence of intesti-
nal dysbiosis, higher prevalence of increased intestinal permeability, bacterial translocation, 
pro-inflammatory molecules, endotoxemia, and cytokines. The hepatic manifestation of the 
dysregulation of insulin-dependent pathways leads to IR and adipose tissue accumulation in 
NAFLD patients with liver injury, indicated that the gut liver-axis is the way by which the 
bacteria and their potential hepatotoxic products (LPS, DNA, RNA, etc.) can easily reach liver 
[105, 106].
The interaction between the gut epithelia and some commensal bacteria induces the rapid 
generation of ROS. The main goal of any therapy addressing NASH is to reverse or prevent 
progression to liver fibrosis/cirrhosis [78]. Recently, a new isoform of human manganese 
superoxide dismutase (MnSOD) has been shown to be a powerful antioxidant capable of 
mediating ROS dismutation, penetrating biological barriers via its uncleaved leader peptide, 
and reducing portal hypertension and fibrosis in rats affected by cirrhosis [107]. Primary bile 
acids which derived from cholesterol become secondary bile acids under the action of intes-
tinal microbes. If the bile acids bind to G-protein-coupled cell surface receptor (TGR5), it 
could inhibit inflammation via suppressing NF-κB pathway in macrophages. Many genetic 
and environmental factors have been suggested to contribute to the development of obesity 
and NAFLD, but the exact mechanisms might be the issue of further investigations [108, 109].
8.2. Toxic substances
NAFLD has been implicated in some conditions such as IR, obesity, metabolic syndrome, 
hyperlipemia, hypertension, cardiovascular disease, and diabetes. Dietary or genetic obesity 
induces alterations of gut microbiota, thereby increasing the levels of deoxycholic acid, a gut 
bacterial metabolite known to cause DNA damage [78, 110]. Glyceraldehyde-derived advanced 
glycation end-products (Glycer-AGEs) are the predominant components of toxic AGEs (TAGE). 
More data suggested that TAGE with its receptor might change intracellular signaling, pro-
inflammatory molecules gene expression, and also elicited the oxidative stress generation in 
liver cells including hHSCs. Circulating TAGE levels were significantly higher in NASH patients 
than those with simple steatosis or healthy subjects. Moreover, their TAGE levels inversely cor-
related with adiponectin. Increased lipid availability in livers might provide ATP and structural 
support for cancerous cell proliferation [111, 112].
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9. NAFLD in hepatocarcinogenesis
Recent epidemiological studies have identified NASH, a progressive form of NAFLD, as a 
major risk factor for HCC. Elucidating the underlying mechanisms associated with the devel-
opment of NASH-derived HCC is critical for identifying early biomarkers for the progression 
of the disease and for treatment and prevention [97, 113].
Liver derangements in lipid metabolism, importing FFA and manufacturing, storing, and 
exporting lipids could lead to NAFLD development [114]. The dysregulation of hormonal axes, 
mitochondrial carnitine palmitoyltransferase-II inactivity, and cytokines in NAFLD promotes 
a worse cycle between metabolic and inflammatory stimulus lead to malignant transformation 
of hepatocytes [33, 71]. The majority of NAFLD patients had steatosis about 20% present as 
NASH that was defined by microscopic finding, and consists of liver injury, steatosis, paren-
chymal and portal inflammation, and different fibrosis. Alterations of miRNA in hepatocar-
cinogenesis were associated with TGF-β, Wnt/β-catenin, ERK1/2, mTOR, and EGF signaling 
pathways. Importantly, miR-93-5p, miR-221-3p, and miR-222-3p were also significantly over-
expressed in human HCC. Aberrant expression of miRNAs might have mechanistic signifi-
cance in NASH-associated liver carcinogenesis and serve as an indicator for the development 
of NASH-derived HCC [115, 116].
Hepatic lipid accumulation is accompanied by distinct patterns of perilipin expression, 
suggested that abnormality of hepatic lipid accumulation might promote hepatocyte 
malignant transformation [33]. The levels of high leptin and low adiponectin are hall-
marks of obesity and involved in NAFLD and carcinogenesis [117]. Obesity-promoted 
HCC occurrence was dependent on increasing IL-6 and TNF levels, which resulted in liver 
inflammation and oncogenic STAT3 activation. The long-term chronic inflammatory in 
obesity plus higher IL-6 and TNF might be the risk factor for HCC [118]. The prospective 
studies (25,337 patients with HCC) demonstrated that both of excess body weight and 
obesity in males or females are related to an increased risk factor for HCC occurrence 
[119]. The prospective studies with longer follow-up periods should screen the malignant 
transformation of hepatocytes with specific biomarkers among NASH or NAFLD popula-
tions [3, 120].
10. Perspectives
In the past decade, the discussion of substantially NAFLD increased by hypernutrition and 
HCC had become a cocktail party cliché, and its impact on public health cannot be dismissed. 
With both relationship gradually deepening, more and more evidences have supported that 
NAFLD might promote the malignant transformation of hepatocytes because of liver lipid 
accumulation, its toxicity, endoplasmic reticulum dysfunction, IR, and abnormal fat metabo-
lism. Although the exact mechanisms from NAFLD tumor-promoting mechanism triggered 
by hypernutrition remain to be explored [121], however, the patients with the excessive fat 
deposition feeds this tumor-promoting inflammatory flame and should be treated in time to 
avoid the occurrences of hepatocyte malignant transformation [7, 122].
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